Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products
ICH Q6B harmonises the specifications — the tests, analytical procedures, and acceptance criteria — that define quality for biotechnological and biological products such as proteins and polypeptides. It addresses the analytical challenges unique to biologics: inherent molecular heterogeneity, the need for orthogonal physicochemical and biological characterisation, potency measured by relevant bioassay, and the separation of product-related from process-related impurities. It sets expectations for well-qualified reference standards and materials. Q6B complements Q6A, which governs chemical drug substances and products, and forms the specification basis a marketing application in the ICH regions must justify.
What this does not cover
stated in the document's own scope- It does not cover chemical drug substances or products — those follow ICH Q6A.
- It does not prescribe the manufacturing process or development approach; ICH Q11 addresses drug-substance development and manufacture.
- It is not a comparability protocol; demonstrating quality after manufacturing changes is governed by the separate ICH comparability guideline.
- It does not necessarily apply to antibiotics, blood and plasma products, or conventional vaccines, which fall outside its stated scope.
Always verify against the current published text before relying on it for a submission or inspection.
Overview
ICH Q6B provides a harmonised approach to setting specifications for biotechnological and biological products across the European Union, Japan, and the United States. Because biologics are large, structurally complex molecules produced in living systems, their quality cannot be captured by a short list of chemical tests. The guideline explains how manufacturers select the tests, procedures, and acceptance criteria that together confirm identity, purity, potency, and quantity. It stresses extensive characterisation, orthogonal methods, and well-qualified reference standards, and it accepts that some heterogeneity is an intrinsic property of the product rather than a defect to be eliminated.
Legal basis & how it acquires force
ICH Q6B is a harmonised guideline, not law in itself; it acquires force when each ICH region adopts it into its own framework. The FDA issued it as guidance for industry in 1999, the EMA adopted it as a CHMP scientific guideline, and Japan's authority issued it by notification. Specifications built on Q6B support the quality section of a marketing application submitted under each region's medicines legislation — for example the US Public Health Service Act and FD&C Act licensing provisions, or the EU medicinal-products Directive and Regulation.
Document structure
| Part | Covers |
|---|---|
| Scope and rationale | Products in scope — proteins, polypeptides, and their derivatives — and the principles for setting biologics specifications |
| Characterisation | Physicochemical properties, biological activity, immunochemical properties, purity, impurities, and quantity |
| Reference standards and materials | Establishment and qualification of primary and working reference standards |
| Specifications and justification | Selecting tests and acceptance criteria and justifying them from development and batch data |
| Analytical procedures and tests | General tests plus product-specific identity, purity, potency, and quantity assays |
Key requirements
- Justify each specification with data from characterisation, batch analysis, and stability studies rather than defaulting to compendial limits.
- Characterise the molecule using orthogonal physicochemical methods that resolve size, charge, and higher-order-structure heterogeneity.
- Establish a relevant potency assay that reflects the product's biological activity and express results against a qualified reference standard.
- Distinguish product-related substances and impurities from process-related impurities, and set acceptance criteria for each class.
- Qualify and maintain primary and working reference standards, documenting their characterisation and traceability.
- Define appropriate acceptance criteria for identity, purity, quantity, and general tests, linking limits to the clinical and manufacturing experience.
- Confirm consistency of the manufacturing process through the specification and its supporting characterisation data.
Implementation tips
- Build a characterisation dossier that maps each quality attribute to the method that measures it, so specifications trace back to data.
- Tie the potency assay to a reference standard qualified early, and plan its replacement bridging before stock runs low.
- Separate product-related and process-related impurity strategies from the outset — they demand different analytical approaches and limits.
- Coordinate Q6B specifications with the comparability exercise so post-change data slots into the same analytical framework.
International alignment
Q6B applies across the EU, Japan, and the United States and is widely referenced by other regulators building biologics frameworks. It complements Q6A for chemical entities and works alongside Q11 on the development and manufacture of drug substances and the ICH quality-of-biotechnological-products series. Regional pharmacopoeias — the Ph. Eur., USP, and JP — supply compendial monographs and general chapters that a Q6B specification may reference where relevant.
ICH Q6B: frequently asked questions
Quick answers to common questions about ICH Q6B.
Does ICH Q6B apply to chemical drugs?
No. Q6B covers biotechnological and biological products such as proteins and polypeptides; chemical drug substances and products follow ICH Q6A.
What products are within Q6B's scope?
Proteins and polypeptides, their derivatives, and products of which they are a component, produced from recombinant or non-recombinant expression systems. It does not necessarily apply to antibiotics, blood products, or conventional vaccines.
Why does Q6B emphasise reference standards?
Because biologics are measured by comparison. Potency and many quality attributes are expressed relative to a qualified reference standard, so its characterisation and continuity underpin the whole specification.
How does Q6B treat product heterogeneity?
It accepts that heterogeneity is often an intrinsic property of biologics. The specification defines and controls the pattern of heterogeneity rather than requiring a single homogeneous species.
When was Q6B finalised?
It reached ICH Step 4 on 10 March 1999 and remains the current harmonised specification guideline for biologics.